In Vitro Activity of the New Triazole BMS-207147 Against Aspergillus Species in Comparison with Itraconazole and Amphotericin B

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Jan 20

PMID 10639380

Citations 11

Authors

C B Moore

C M Walls

D W Denning

Affiliations

Soon will be listed here.

Abstract

The in vitro activity of BMS-207147 against 80 clinical isolates of Aspergillus was compared with that of itraconazole and amphotericin B, using a validated microtiter method. Geometric mean MICs (in microg/ml) were as follows: 1.71 for BMS-207147, 0.67 for itraconazole, and 0.63 for amphotericin B. The range of concentrations of each drug was 0.125 to >16 microg/ml. Aspergillus fumigatus was significantly more susceptible to BMS-207147 (P < 0. 05) than A. terreus and A. flavus. No BMS-207147-resistant A. fumigatus isolates were identified, though eight itraconazole-resistant (MIC, >8 microg/ml) isolates were. BMS-207147 is active against Aspergillus spp. at slightly high concentrations compared with itraconazole and amphotericin B.

Citing Articles

Treatment and prophylaxis of invasive candidiasis.

Tripathi N, Watt K, Benjamin Jr D Semin Perinatol. 2012; 36(6):416-23.

PMID: 23177800 PMC: 3582379. DOI: 10.1053/j.semperi.2012.06.003.

Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.

Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E Curr Drug Metab. 2012; 14(2):193-202.

PMID: 22935068 PMC: 3541435.

Epidemiology and antifungal resistance in invasive Aspergillosis according to primary disease: review of the literature.

Mayr A, Lass-Florl C Eur J Med Res. 2011; 16(4):153-7.

PMID: 21486729 PMC: 3352071. DOI: 10.1186/2047-783x-16-4-153.

Pharmacokinetics of antifungal agents in children.

Watt K, Benjamin Jr D, Cohen-Wolkowiez M Early Hum Dev. 2011; 87 Suppl 1:S61-5.

PMID: 21277714 PMC: 3418808. DOI: 10.1016/j.earlhumdev.2011.01.014.

Proteomic and transcriptomic analysis of Aspergillus fumigatus on exposure to amphotericin B.

Gautam P, Shankar J, Madan T, Sirdeshmukh R, Sundaram C, Gade W Antimicrob Agents Chemother. 2008; 52(12):4220-7.

PMID: 18838595 PMC: 2592866. DOI: 10.1128/AAC.01431-07.

References

Pfaller M, Messer S, Hollis R, Jones R, Doern G, Brandt M . In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob Agents Chemother. 1998; 42(12):3242-4. PMC: 106028. DOI: 10.1128/AAC.42.12.3242. View

Johnson E, Oakley K, Radford S, Moore C, Warn P, Warnock D . Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother. 2000; 45(1):85-93. DOI: 10.1093/jac/45.1.85. View

Morrison V, Haake R, Weisdorf D . Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med. 1994; 96(6):497-503. DOI: 10.1016/0002-9343(94)90088-4. View

Berenguer J, Ali N, Allende M, Lee J, Garrett K, Battaglia S . Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother. 1994; 38(6):1303-8. PMC: 188202. DOI: 10.1128/AAC.38.6.1303. View

Hata K, Kimura J, Miki H, Toyosawa T, Nakamura T, Katsu K . In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum. Antimicrob Agents Chemother. 1996; 40(10):2237-42. PMC: 163510. DOI: 10.1128/AAC.40.10.2237. View

Hata K, Kimura J, Miki H, Toyosawa T, Moriyama M, Katsu K . Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother. 1996; 40(10):2243-7. PMC: 163511. DOI: 10.1128/AAC.40.10.2243. View

Oakley K, Moore C, Denning D . In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother. 1998; 42(1):91-4. DOI: 10.1093/jac/42.1.91. View

Oakley K, Moore C, Denning D . In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother. 1997; 41(5):1124-6. PMC: 163861. DOI: 10.1128/AAC.41.5.1124. View

Oakley K, Morrissey G, Denning D . Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother. 1997; 41(7):1504-7. PMC: 163948. DOI: 10.1128/AAC.41.7.1504. View

10.

Denning D, Radford S, Oakley K, Hall L, Johnson E, Warnock D . Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother. 1997; 40(3):401-14. DOI: 10.1093/jac/40.3.401. View

11.

Fung-Tomc J, Huczko E, Minassian B, Bonner D . In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother. 1998; 42(2):313-8. PMC: 105406. DOI: 10.1128/AAC.42.2.313. View

12.

Denning D . Invasive aspergillosis. Clin Infect Dis. 1998; 26(4):781-803; quiz 804-5. DOI: 10.1086/513943. View

13.

Martin M, Yates J, Hitchcock C . Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother. 1997; 41(1):13-6. PMC: 163652. DOI: 10.1128/AAC.41.1.13. View